Metastatic cutaneous squamous cell carcinoma (SCC) of the head and neck poses a significant therapeutic challenge due to its aggressive biologic behavior. We conducted a retrospective study of 71 patients-58 men and 13 women, aged 28 to 88 years (mean: 71)who had been treated at our university-affiliated tertiary care medical center for metastatic cutaneous SCC over a 15-year period. In addition to demographic data, we compiled and analyzed information on tumor characteristics, the site and extent of metastasis, treatment, follow-up, and outcome. Among the tumor factors, poorly differentiated carcinoma was an independent predictor of poorer disease-free survival, and older age was found to be an independent predictor of poorer overall survival. We found no significant difference in disease-free or disease-specific survival among patients with parotid involvement, neck involvement, or both. In our series, the site of nodal involvement appeared to have no prognostic significance in patients with metastatic cutaneous SCC of the head and neck.
Introduction
Cutaneous squamous cell carcinoma (SCC) has the potential to metastasize to regional lymph nodes. 1 Uncontrolled metastatic nodal disease and, to a lesser extent, distant metastases account for the mortality and morbidity associated with this disease. The parotid and upper cervical lymph nodes are frequent sites for the development of metastases arising from SCC of the ear, anterior scalp, temple/forehead, and scalp. 2 Parotid-area lymph node metastases require aggressive therapy, sometimes with selective neck dissection. 3 The addition of adjuvant radiotherapy in some cases has been associated with better regional control rates and is generally well tolerated. 4, 5 O'Brien et al found cervical node involvement to be a major predictor of outcome in cutaneous SCC. 6 Several studies have suggested that planning treatment in patients with metastatic cutaneous SCC is difficult because the current staging system is not specific for head and neck tumors and it fails to describe the extent of locoregional disease. [7] [8] [9] [10] Ebrahimi et al suggested that selective neck dissection for clinically negative neck patients undergoing parotidectomy for metastatic cutaneous SCC should include levels I to III for facial primaries, levels II and III for anterior scalp and external ear primaries, and levels II to V for posterior scalp and neck primaries. 11 Nevertheless, the extent of surgery and the use of adjuvant radiotherapy are still debatable, and the contribution of large-volume studies from tertiary care centers in warm-climate countries cannot be underestimated.
We conducted a retrospective study to review our experience and to further clarify the clinical behavior and management of metastatic cutaneous SCC of the head and neck. Secondarily, we tried to determine whether the site of regional recurrence has any prognostic significance.
Patients and methods
We reviewed the computerized files of our large university-affiliated tertiary care medical center to identify all patients who had been treated for cutaneous SCC of the head and neck with regional lymph node metastasis over a 15-year period. We compiled and analyzed information on demographic factors, tumor characteristics, the site and extent of metastasis, treatment, follow-up, and outcome. Patients whose data were insufficient and those who had been followed for less than 3 years were excluded from out study. Our final study population was made up of 71 patients-58 men and 13 women, aged 28 to 88 years (mean: 71). the primary tumor site was completely resected before the regional disease was detected;
in the remaining 7 patients, metastatic disease had been diagnosed simultaneously with the primary skin lesion, so a wide local excision was needed.
All patients had undergone a thorough evaluation of the extent of their disease by ultrasonography and computed tomography. Extracapsular spread was noted in 13 metastatic lymph nodes-9 in the neck and 4 in the parotid gland. The three most common sites of neck metastasis were levels II, III, and V, in that order.
Adjuvant treatment.
Following surgery, all patients received adjuvant radiotherapy.
Doses ranged from 46 to 80 Gy (median: 60) to the parotid and from 46 to 76 Gy (median: 50) to the neck.
Recurrence and survival. The duration of follow-up ranged from 36 to 71 months (mean: 6.1 yr). The disease-free survival at 5 years was 63.3% for the 37 patients with parotid involvement, 83.3% for the 8 patients with parotid and neck involvement, and 57.8%
for the 26 patients with neck involvement only. There were no significant differences in 5-year survival among these groups (p = 0.832) ( figure 1) .
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Thirteen patients (18.3%) died of their disease. No significant difference in diseasespecific survival was noted according to site of regional involvement (p = 0.652) (figure 2).
Cox proportional hazard regression analysis revealed that poorly differentiated carcinoma was the only independent predictor of significantly worse disease-free survival.
Compared with well-differentiated carcinoma, the hazard ratio (HR) for poorly differentiated carcinoma was 8.12 with a 95% confidence interval (CI) of 1.03 to 63.85 (p = 0.047) (table 2) .
Thirty-six patients died during follow-up. The 5-year overall survival was 52%. Cox proportional hazard regression analysis revealed that older age was an independent predictor of worse survival (HR: 1.05; 95% CI: 1.01 to 1.09; p = 0.008) (table 3) .
Discussion
Metastatic cutaneous SCC of the head and neck involving the parotid gland and neck is an aggressive disease with a tendency toward an infiltrative growth pattern and multiple recurrences. 12 Rowe et al found that metastatic cutaneous SCC involving the parotid gland was associated with a high incidence of clinical and occult neck disease. 13 They therefore suggested that in the presence of parotid involvement, treatment of the clinically negative neck should be considered in order to reduce the likelihood of failure in the cervical nodes,
to define the extent of the disease, and to assist in patient selection for adjuvant therapy.
Andruchow et al reported a significantly worse prognosis for patients with metastatic
cutaneous SCC in both the parotid gland and neck than for those whose disease was limited to the parotid gland alone. 14 O'Brien et al recommended that the clinical staging system for cutaneous SCC of the head and neck should be modified to distinguish parotid disease (P) and neck disease (N). 15 However, other authors questioned the benefit of this practice, although they agreed it might better identify patients with unfavorable characteristics. Others have proposed that instead of categorizing lymph node metastasis from cutaneous SCC simply as N, the extent of the disease should be incorporated in the staging system. 16, 17 In our study, we found no significant difference in either disease-free or diseasespecific survival among patients with metastatic disease in the parotid gland alone, in the neck alone, or both. Furthermore, the extent of metastatic disease in the parotid gland and neck did not correlate with local control rates or disease-specific survival in a multivariate analysis. The only independent predictor of a high risk of recurrence was poorly differentiated metastatic carcinoma. Extracapsular spread was more common in neck lymph node metastasis than in parotid gland metastasis, but the difference in terms of survival did not reach statistical significance.
Multivariate analysis also showed that only older age was an independent predictor of worse survival. This finding was not a result of the high rate of regional recurrence rather than increased perioperative morbidity and mortality associated with older age. This finding emphasizes the importance of considering the host factor when treating elderly patients with metastatic cutaneous SCC, as they are more likely to be susceptible to comorbidities and postoperative complications.
Our findings are consistent with those of previous studies that found that the overall risk of recurrence is high in patients with metastatic cutaneous SCC. 18 This is also consistent with the findings of other authors who have advocated combining surgery with adjuvant radiotherapy in order to improve regional control. 19, 20 We conclude that the site of involvement in metastatic cutaneous SCC appears to have no prognostic significance in terms of disease-free survival and disease-specific survival.
Surgery remains the best treatment practice in metastatic cutaneous SCC, providing the best chance of achieving locoregional control. More aggressive surgery may be justified to reduce the risk of regional failure after parotidectomy and neck dissection in patients with poorly differentiated tumors. Since older patients tend to experience more perioperative mortality and have a lower overall survival rate, a thorough risk stratification for these patients is paramount. 
